NINLARO®

Hold Company

TAKEDA PHARMS USA

Learn More

Dosage and Administration

CAPSULE;ORAL

Specification

EQ 2.3MG BASE; EQ 3MG BASE; EQ 4MG BASE

Indication

NINLARO® is indicated for patients with multiple myeloma who have received at least one prior therapy for combination therapy.

Use

Instructions for Use

API

IXAZOMIB CITRATE

API Structure

We Supply

IXAZOMIB CITRATE

Note:

null

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
7442830	2029/11/20
7687662	2027/8/6
8003819	2027/8/6
8530694	2027/8/6
8546608	2024/8/12
8859504	2029/6/16
8871745	2027/8/6
9175017	2029/6/16
9233115	2024/8/12

API Patent

Patent No	Expiration Date
7687662	2027/8/6
8003819	2027/8/6
8530694	2027/8/6
8546608	2024/8/12
8859504	2029/6/16
8871745	2027/8/6
9175017	2029/6/16
9233115	2024/8/12

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.